In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...

Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR ...

Gain insights into the operational challenges facing clinical research sites today, learn what sponsors and CROs can do to ...

ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...

Strong relational governance between technology vendors and sponsor–CRO teams is becoming a critical foundation for eCOA ...

New FDA guidance signals a major shift for CAR-T development, calling for randomized trials with standard-of-care control groups and clear evidence of superiority over existing therapies, while ...

In today’s ACT Brief, we look at how AI and in-silico methods are reshaping drug repurposing, why staggered ICH GCP rollouts ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

Chen: Yes, obesity is experiencing accelerated growth over the last couple of years. According to our sister product Evaluate ...

Gain insights into the operational challenges facing clinical research sites today, learn what sponsors and CROs can do to reduce burden, and explore how evolving collaboration models and technology ...